Evidence map›Paper›PMID 40911045›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Repurposing rupatadine to attenuate ovarian ischemia reperfusion in rats through modulation of PAF/NF-κB/TNF-α/IL-1β; HIF-1α/VEGF/Caspase 3 signaling pathways.

Hanaa Mohamed Khalaf, Sara M Ahmed, Alyaa Abdelfattah Abdelmonaem, Rabeh Khairy Saleh, Abdelaleem Abdelnour Mohamed, AbdelHamid Sayed AboBakr Ali, Mohamed Adel, Heba Reda Mohamed, Heba S Kamel, Walaa Yehia Abdelzaher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanaa Mohamed KhalafDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Sara M AhmedDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Alyaa Abdelfattah AbdelmonaemDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Rabeh Khairy SalehDepartment of Pathology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Abdelaleem Abdelnour MohamedDepartment of Medical Physiology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
AbdelHamid Sayed AboBakr AliDepartment of Anatomy, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Mohamed AdelDepartment of Obstetrics & Gynecology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Heba Reda MohamedDepartment of Obstetrics & Gynecology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Heba S KamelDepartment of Medical Biochemistry, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Walaa Yehia AbdelzaherDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, 61519, Egypt. walaa.hamada@mu.edu.eg.ORCID http://orcid.org/0000-0001-6511-1797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the current study is to identify the possible protective effect of rupatadine (RUP) on ovarian ischemia reperfusion (OIR) in rats. RUP was administered in the presence and absence of OIR. Thirty-two adult Wistar albino female rats were randomly arranged into four groups: Sham, RUP (6 mg/kg/day) for 14 days, OIR and OIR + RUP groups.The results demonstrated that OIR significantly lowered serum anti-mullerian hormone level and ovarian total antioxidant capacity. Besides, a significant elevation in serum follicle stimulating hormone, lutenizing hormone, ovarian malondialdehyde level, hypoxia-inducible factor-1(HIF-1α), platelet activating factor (PAF), tumor necrosis factor-alpha (TNF-α), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interleukin 1beta (IL-1β) levels along with an evident increase in ovarian vascular endothelial growth factor (VEGF) and caspase-3 immunoexpression. While, OIR + RUP pretreated group showed a reversal in OIR damaging effects in a significant manner in all the aforementioned parameters. Based on these findings; RUP has powerful anti-IR actions by lowering oxidative stress, inflammation, and apoptosis via modulation of the PAF/ NF-κB/TNF-α/ IL-1β; HIF-1α/ VEGF / Caspase 3 signaling pathways.

Indexed as

CyproheptadineOvaryReperfusion InjuryAnimalsCaspase 3FemaleHypoxia-Inducible Factor 1, alpha SubunitInterleukin-1betaNF-kappa BPlatelet Activating FactorRatsRats, WistarSignal TransductionTumor Necrosis Factor-alphaVascular Endothelial Growth Factor ACasp3 protein, ratCaspase 3CyproheptadineHif1a protein, ratHypoxia-Inducible Factor 1, alpha SubunitInterleukin-1betaNF-kappa BPlatelet Activating FactorrupatadineTumor Necrosis Factor-alphaVascular Endothelial Growth Factor Avascular endothelial growth factor A, ratHIF-1αOvarian ischemia reperfusionPAFRupatadineVEGF

Identifiers

PMID40911045
PMCPMC12901094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.